After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million). | After nearly nine years ...

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise ...

The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

Emma Walmsley has served as CEO of GlaxoSmithKline since 2017. From the Philadelphia Business Journal. GSK is making a change at the top. The London-based Big Pharma company, which has major ...

GSK on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing ...

GSK is scheduled to report results for the fourth quarter of 2025 on Wednesday. Here is what you need to know. SALES FORECAST: The U.K. drugmaker is expected to post fourth-quarter sales of 8.495 ...

LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker will aim to lift sales growth and speed up work on new medicines in its next phase of growth through a sharper ...

"After you take some well-deserved time off … let's do it again!" the chair of RAPT Therapeutics' board tells co-founder-CEO ...